

Cover Story
Free
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, a Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
In Brief


Drugs & Targets
Trending Stories
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74











